CN115916204A - 用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法 - Google Patents
用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法 Download PDFInfo
- Publication number
- CN115916204A CN115916204A CN202080101284.7A CN202080101284A CN115916204A CN 115916204 A CN115916204 A CN 115916204A CN 202080101284 A CN202080101284 A CN 202080101284A CN 115916204 A CN115916204 A CN 115916204A
- Authority
- CN
- China
- Prior art keywords
- agents
- day
- dose
- cov
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 15
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 11
- 230000009385 viral infection Effects 0.000 title claims abstract description 11
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 8
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229950008454 favipiravir Drugs 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 3
- 238000002651 drug therapy Methods 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940035676 analgesics Drugs 0.000 claims description 6
- 230000000954 anitussive effect Effects 0.000 claims description 6
- 239000000730 antalgic agent Substances 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 239000003434 antitussive agent Substances 0.000 claims description 6
- 229940124584 antitussives Drugs 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 229940124301 concurrent medication Drugs 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 208000020446 Cardiac disease Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 230000001142 anti-diarrhea Effects 0.000 claims description 3
- 239000003793 antidiarrheal agent Substances 0.000 claims description 3
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 239000000157 antineoplastic hormone Substances 0.000 claims description 3
- 239000003904 antiprotozoal agent Substances 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229940032954 corticosteroids for systemic use Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 229940124299 hormone/antineoplastic Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 230000036454 renin-angiotensin system Effects 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 208000021510 thyroid gland disease Diseases 0.000 claims description 3
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 239000003058 plasma substitute Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 238000011301 standard therapy Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 4
- 229960004099 azithromycin Drugs 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000005660 Abamectin Substances 0.000 description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 3
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000009341 RNA Virus Infections Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及新的用于治疗RNA病毒感染(包括COVID‑19(SARS‑CoV‑2))的方法。用于治疗RNA病毒感染(包括COVID‑19(SARS‑CoV‑2))的方法,其包括向患者施用以片剂、胶囊、丸剂或粉剂形式的包含法匹拉韦(Favipiravir)作为活性成分的药学组合物,在第1天以≥40mg/kg/天的剂量和在随后的天以≥16mg/kg/天的剂量,直至病毒离开身体,任选地与伴随的药物治疗相组合地。
Description
技术领域
本发明涉及新的用于治疗RNA病毒感染(包括COVID-19(SARS-CoV-2))的方法。
现有技术
存在已知的用于治疗RNA病毒感染(包括禽流感的高致病性AH5N1毒株)的方法[R.W.Sidwell等人,Antimicrob.Agents Chemother.2007,51(3):845-851],其中使用由日本公司Toyama Chemical Co于1999年获得专利[RU 2224520]的法匹拉韦(Favipiravir;FVP)药物(也称为Т-705和Avigan)。FVP显示出针对许多其他RNA病毒的抗病毒活性,例如沙粒病毒、布尼亚病毒和线状病毒,它们已知引起致命的埃博拉出血热[Y.Furuta等人,Review Favipiravir(T-705),a broad spectrum inhibitor of viral RNApolymerase.Proc.Jpn.Acad.,Ser.B 93,2017,449-463;L.Oestereich等人,Ebola virusinfection with T-705(favipiravir)in a small animal model.Antiviral Research2014,105,17-21]。
在日本以商品名Avigan(Avigan片剂200mg,受到俄罗斯专利RU 2527766保护,其中声称在所述片剂中的FVP含量为50-95%)和在中国以商品名法维拉韦(Favilavir)(法维拉韦片剂200mg)进行销售的FVP是一种在日本用于治疗流感的抗病毒药物。它由ToyamaChemical Co(FujiFilm Group)开发和生产(现在),并且它在2014年在日本被批准用于医学用途[Shiraki K.,Daikoku T.Favipiravir,an anti-influenza drug against life-threatening RNA virus infections.Pharmacology&Therapeutics 2020,107512.doi:10.1016/j.pharmthera.2020.107512]。
2019年新型冠状病毒(后来被命名为SARS-CoV-2)的突然爆发(其很快变为全球大流行)标志着有毒力的冠状病毒第三次引入人类社会,不仅影响卫生系统,而且影响世界经济。关于SARS-CoV-2(COVID-19)的疫苗接种、预防和治疗的有效方法和流行病学控制仍然还不存在。
在这方面,对于用于预防和治疗RNA病毒感染(包括SARS-CoV-2(COVID-19))的疫苗和治疗试剂正在进行密集的全世界探索。作为对于出现的大流行的快速响应的一种实际方法是改变现存的先前意欲用于其他病毒感染的治疗试剂的用途,因为这些试剂中的大部分已经就其安全性进行了测试。
用于治疗RNA病毒感染的常见方法是口服施用以片剂、胶囊、粉末等形式的包含FVP作为活性成分的药学组合物,其中FVP日剂量宽范围地变化。例如,为了治疗流感,以在第一天1800mg每天两次和然后800mg每天两次持续2-5天的剂量使用FVP[https://www.medrxiv.org/content/medrxiv/early/2020/04/08/2020.03.17.20037432.full.pdf];而为了治疗埃博拉病毒感染,以在第一天每8个小时2400mg、2400mg和1200mg的剂量给予FVP,和每天两次给予1200mg的维持剂量[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)71047-3/fulltext]。
为了治疗SARS-CoV-2感染(COVID-19),如下使用FVP:
-以在第一天1600mg每天两次和然后600mg每天两次持续14天的剂量[https://www.jwatch.org/na51293/2020/04/09/favipiravir-potential-antiviral-covid-19.clinicaltrials.gov/ct2/show/NCT04349241;https://www.medicalnewstoday.com/articles/anti-flu-drug-effective-in-treating-covid-19#Favipiravir-maycombat-SARS-CoV-2.file:///C:/Users/av/Downloads/Experimental_Treatment_with_Favipiravir_for_COVID-%20(1).pdf.https://www.precisionvaccinations.com/vaccines/avigan-antiviral-medication.];
-以在第一天1800mg每天两次和然后800mg每天两次持续14天的剂量[https://bgr.com/2020/04/17/coronavirus-update-antiviral-tablet-avigan-clinical-trial/.https://theprint.in/health/glenmark-enrols-150-patients-to-test-favipiravir-the-most-sought-after-drug-for-covid/420019/.]。
已发现,在口服接受FVP(第1天:1600mg每天两次;第2-14天:600mg每天两次,14天)加上吸入α-干扰素气溶胶(5百万单位每天两次)的具有确诊的COVID-19的患者的联合治疗中,取得了4天(2.5-9)的病毒清除,相对于关于接受洛匹那韦/利托那韦(ritanovir)(400mg/100mg每天两次)的对照患者组的11天(8-13)而言[file:///C:/Users/av/Downloads/Experimental_Treatment_with_Favipiravir_for_COVID-%20(1).pdf]。
还已知,以30mg/kg/天的剂量在2-4个分开的剂量中使用FVP[https://emedz.net/antiviral-drugs-for-the-treatment-of-covid-19-infection/]。
2020年2月,在中国在用于冠状病毒SARS-CoV-2(COVID-19)的抗病毒疗法的随机化试验中成功地测试了FVP。2020年2月,FVP在中国被批准作为针对COVID-19的有效的抗病毒试剂[https://de.wikipedia.org/wiki/Favipiravir]。
到2020年5月22日为止,全世界被COVID-19感染的人数为5,214,971人,其中335,002人死亡和2,094,920人恢复。按冠状病毒病例数,前10个国家为:美国(1,621,333)、俄罗斯(326,448)、巴西(310,921)、西班牙(280,117)、英国(250,908)、意大利(228,006)、法国(181,826)、德国(179,110)、土耳其(153,548)、伊朗(129,341)[https://sport24.ru/news/zozh/2020-05-22-koronavirus-na-22-maya-statistika-v-mire-onlayn-rossiya-karta-na-segodnya]。
鉴于SARS-CoV-2对于全世界的公共卫生和经济具有严重的威胁,看起来寻找新的用于RNA病毒感染的治疗方法是合适的。
发明公开
本发明的目标是用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法,其包括向被RNA病毒感染的患者施用以片剂、胶囊、丸剂或粉剂形式的药学组合物,所述药学组合物包含法匹拉韦作为活性成分,在第1天以≥40mg/kg/天的剂量和在随后的天以≥16mg/kg/天的剂量,直至病毒离开身体,任选地与伴随的药物治疗相组合地。
对于体重小于75kg的患者,更优选的剂量为:在第1天1600mg每天2次,和在随后的天600mg每天2次,直至病毒离开身体。
对于体重为75kg至90kg(包括端点)的患者,更优选的剂量为:在第1天2000mg每天2次,和在随后的天800mg每天2次,直至病毒离开身体。
对于体重大于90kg的患者,更优选的剂量为:在第1天2400mg每天2次,和在随后的天1000mg每天2次,直至病毒离开身体。
取决于患者的状况,可以施用伴随的药物治疗,包括:镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药和抗感冒试剂、β-受体阻滞剂、维生素、利尿药、用于治疗与酸性受损相关的疾病的药物、影响肾素-血管紧张素系统的药物、用于糖尿病的药物、钙通道阻滞剂、用于全身使用的皮质类固醇、用于心脏疾病的药物、止泻药、抗原生动物药、免疫抑制剂、用于甲状腺疾病的药物、用于阻塞性呼吸系统疾病的药物、抗肿瘤激素药物、降血脂药、其他用于胃肠疾病和代谢紊乱的药物。
优选的伴随的药物治疗为镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药、抗感冒试剂和维生素。
包含FVP作为活性成分的药物阿维法韦(Avifavir)的临床研究显示,在治疗开始后4天具有阴性的关于SARS-CoV-2的PCR测试结果的患者中,在第1天每1kg体重的FVP中值日剂量为44mg/kg,和在具有阳性结果的患者中,为39mg/kg。对于在第1天≥43mg/kg的FVP剂量,病毒消除率为79%,和在具有<43mg/kg的剂量的患者中,为44%。在患者中病毒的中值消除花费4天,而对于用标准疗法进行治疗的患者花费9天。在68%的服用阿维法韦的患者中,体温在第3天变得正常,而在对照组中,体温在第6天变得正常。在经阿维法韦治疗的患者中平均病毒清除花费4天,而在标准疗法组中花费9天。在治疗的头4天后,在用阿维法韦进行治疗的40名患者中的65%具有阴性的关于冠状病毒的测试结果,这是在标准疗法组中(30%)的2倍。到第10天,具有阴性测试结果的患者数目达到40名中的35名。
发明的优选实施方案
通过但不限于下面的实施例来对本发明进行举例说明。
实施例:在因COVID-19住院的中等严重度患者中,阿维法韦的功效和安全性的适应的、多中心的、随机化的、标签公开的、比较性的临床研究
研究目的:基于SARS-CoV-2消除的速度来评价阿维法韦(包含200mg的FVP作为活性成分的片剂[07.05.20的专利申请RU 2020116521])的抗病毒效应。
该研究牵涉60名具有确诊的中等严重度的新型冠状病毒感染(COVID-19)的患者,其被接收进临床中心的感染部。
将患者随机分入3个研究疗法组。组1(20名患者):FVP剂量为在第1天1600mg 2次,然后600mg每天2次持续13天。组2(20名患者):FVP剂量为在第1天1800mg 2次,然后800mg每天2次持续13天。
取决于状况,连同FVP一起,所述两个组的患者均采用伴随的药物治疗,包括:镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药和抗感冒试剂、β-受体阻滞剂、维生素、利尿药、用于治疗与酸性受损相关的疾病的药物、影响肾素-血管紧张素系统的药物、用于糖尿病的药物、钙通道阻滞剂、用于全身使用的皮质类固醇、用于心脏疾病的药物、止泻药、抗原生动物药、免疫抑制剂、用于甲状腺疾病的药物、用于阻塞性呼吸系统疾病的药物、抗肿瘤激素药物、降血脂药、其他用于胃肠疾病和代谢紊乱的药物。
最经常地,连同FVP一起,所述患者采用伴随的药物治疗,其选自下述这一系列:镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药、抗感冒试剂和维生素。
取决于具体的患者状况,标准疗法组的患者(20人)采用氯喹、阿奇霉素、阿莫西林克拉维酸(Amoxiclav)、阿奇霉素+羟氯喹、阿奇霉素+头孢曲松或者阿奇霉素+洛匹那韦+利托那韦。
在被纳入该研究中之时,27%的患者需要氧气支持,和37%的患者处于严重疾病的风险中(年龄超过60岁和/或存在慢性共存病)。从第一症状发作到该研究疗法开始的该疾病平均持续时间为7天。在该疾病的最常见的症状中包括:超过37.5°的发热(95%)、咳嗽(83%)、无力(70%)、嗅觉缺失(35%)、胸闷(30%)和呼吸短促(28%)。初始参数指明了在标准疗法组中稍微较轻的疾病过程(在95%的患者中,在45%的年轻患者中,在正常范围内的饱和)。
包含FVP作为活性成分的药物阿维法韦的临床研究显示,在治疗开始后4天具有阴性的关于SARS-CoV-2的PCR测试结果的患者中,在第1天每1kg体重的FVP中值日剂量为44mg/kg,和在具有阳性测试结果的患者中,为39mg/kg。对于在第1天≥43mg/kg的FVP剂量,病毒消除率为79%,和在采用<43mg/kg的患者中,为44%。在患者中中值病毒消除花费4天,而在标准疗法的情况下花费9天。在68%的服用阿维法韦的患者中,体温在第3天变得正常,而在对照组中,体温在第6天变得正常。在经阿维法韦治疗的患者中平均病毒清除花费4天,而在标准疗法组中花费9天。在治疗的头4天后,在用阿维法韦进行治疗的40名患者中的65%具有阴性的关于冠状病毒的测试结果,这是在标准疗法组中(30%)的2倍。到第10天,具有阴性测试结果的患者数目达到40名中的35名。
工业适用性
本发明可以在医学和兽医学中使用。
Claims (6)
1.用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法,其包括向患者施用以片剂、胶囊、丸剂或粉剂形式的包含法匹拉韦作为活性成分的药学组合物,在第1天以≥40mg/kg/天的剂量和在随后的天以≥16mg/kg/天的剂量,直至病毒离开身体,任选地与伴随的药物治疗相组合地。
2.根据权利要求1的方法,其中向体重小于75kg的患者施用的法匹拉韦的剂量为在第1天1600mg每天2次,和在随后的天600mg每天2次。
3.根据权利要求1的方法,其中向体重为75kg至90kg的患者施用的法匹拉韦的剂量为在第1天2000mg每天2次,和在随后的天800mg每天2次。
4.根据权利要求1的方法,其中向体重大于90kg的患者施用的法匹拉韦的剂量为在第1天2400mg每天2次,和在随后的天1000mg每天2次。
5.根据权利要求1-4中任一项的方法,其中施用伴随的药物治疗,其选自下述这一系列:镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药和抗感冒试剂、β-受体阻滞剂、维生素、利尿药、用于治疗与酸性受损相关的疾病的药物、影响肾素-血管紧张素系统的药物、用于糖尿病的药物、钙通道阻滞剂、用于全身使用的皮质类固醇、用于心脏疾病的药物、止泻药、抗原生动物药、免疫抑制剂、用于甲状腺疾病的药物、用于阻塞性呼吸系统疾病的药物、抗肿瘤激素药物、降血脂药、其他用于胃肠疾病和代谢紊乱的药物。
6.根据权利要求5的方法,其中所述伴随的药物治疗选自下述这一系列:镇痛药、抗凝血药、用于全身使用的抗细菌药物、代血浆溶液和灌注溶液、止咳药、抗感冒试剂和维生素。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020117666 | 2020-05-23 | ||
RU2020117666 | 2020-05-23 | ||
PCT/RU2020/000321 WO2021242134A1 (ru) | 2020-05-23 | 2020-06-30 | Способ лечения рнк вирусных инфекций, в том числе covid-19 (sars-cov-2) |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115916204A true CN115916204A (zh) | 2023-04-04 |
Family
ID=78744968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080101284.7A Pending CN115916204A (zh) | 2020-05-23 | 2020-06-30 | 用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230158020A1 (zh) |
EP (1) | EP4154887A4 (zh) |
JP (1) | JP2023527798A (zh) |
CN (1) | CN115916204A (zh) |
WO (1) | WO2021242134A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2407166T1 (sl) * | 2009-03-13 | 2013-12-31 | Toyama Chemical Co., Ltd. | Tableta in granuliran praĺ ek, vsebujoäśa 6-fluoro-3-hidroksi-2-pirazinkarboksamid |
US10098879B2 (en) * | 2015-01-28 | 2018-10-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of ebola virus disease |
KR20210080413A (ko) * | 2018-10-17 | 2021-06-30 | 코크리스탈 파마, 아이엔씨. | 인플루엔자 바이러스 복제 억제제의 조합물 |
-
2020
- 2020-06-30 WO PCT/RU2020/000321 patent/WO2021242134A1/ru unknown
- 2020-06-30 US US17/916,805 patent/US20230158020A1/en not_active Abandoned
- 2020-06-30 CN CN202080101284.7A patent/CN115916204A/zh active Pending
- 2020-06-30 JP JP2022572395A patent/JP2023527798A/ja active Pending
- 2020-06-30 EP EP20937996.5A patent/EP4154887A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4154887A4 (en) | 2024-07-03 |
JP2023527798A (ja) | 2023-06-30 |
US20230158020A1 (en) | 2023-05-25 |
WO2021242134A1 (ru) | 2021-12-02 |
EP4154887A1 (en) | 2023-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230081837A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection | |
JP2017514911A5 (zh) | ||
JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
Khubchandani et al. | Emerging therapeutic options for COVID-19 | |
CN115916204A (zh) | 用于治疗包括COVID-19(SARS-CoV-2)在内的RNA病毒感染的方法 | |
Kong et al. | Safety of individual medication of Ma Qian Zi (semen strychni) based upon assessment of therapeutic effects of Guo's therapy against moderate fluorosis of bone | |
EP3977989A1 (en) | Composition for the treatment of novel corona virus disease (covid-19) | |
Azka et al. | Antiviral Therapy in Corona Virus Disease-19 (Covid-19) | |
CN106336447B (zh) | 南蛇藤素的应用 | |
RU2763024C1 (ru) | Мефлохин и его комбинации для лечения и профилактики коронавирусной инфекции | |
CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
Indra et al. | Current scenario for management on COVID-19—A global review | |
WO2009118706A2 (en) | The treatment of helminthic infections | |
WO2022216172A1 (ru) | Водная апротинин-содержащая противовирусная фармацевтическая композиция | |
JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
Sowmya | Drugs used against COVID-19 | |
US20230000884A1 (en) | Combination therapy for treating covid-19 | |
WAHAB | EMERGING THERAPEUTIC STRATEGIES FOR CORONAVIRUS DISEASE 2019 | |
Chaudhry et al. | A Review on the Advancements in COVID-19 Treatments and Vaccines | |
Manjuladevi et al. | Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research | |
CH694687A5 (de) | Arzneimittel zur Behandlung von Virusinfektionen aus Vernonia Oligocephalus. | |
SU701639A1 (ru) | Способ лечени бронхиальной астмы | |
CN105902538A (zh) | 一种治疗或预防口腔溃疡药物组合物及其制备方法和应用 | |
WO2021224790A1 (en) | Vsv (vitamin c-spirulina-vitamin d) composition, kit and method | |
UA146741U (uk) | Спосіб лікування бетакоронавірусної інфекції |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230404 |